Incorporated in 2002, Mahamaya Lifesciences Limited manufactures, registers, and exports crop protection products and bioproducts focused on crop and soil health management to boost farming productivity. The company specializes in pesticide formulations and supplies bulk products to Indian agrochemical companies and multinational corporations.
Mahamaya Lifesciences IPO
BSE SME book‑built issue (Fresh + Offer for Sale + Market Maker)
UPCOMING IPOMahamaya Lifesciences IPO is a book build issue of ₹70.44 crore, consisting of a fresh issue of 0.56 crore shares aggregating to ₹64.28 crore and an offer for sale of 0.05 crore shares aggregating to ₹6.16 crore. The IPO opens on November 11, 2025 and closes on November 13, 2025. The allotment is expected on November 14, 2025, with a tentative listing on BSE SME on November 18, 2025. The price band is ₹108 to ₹114 per share.
The minimum retail application is for 1,200 shares, requiring an investment of ₹2,73,600. The minimum lot size investment for HNI is 3 lots (3,600 shares) amounting to ₹4,10,400. The issue includes 3,09,600 shares reserved for Market Maker Mansi Share & Stock Broking Pvt. Ltd.
| Face Value | ₹10 per share |
|---|---|
| Issue Price Band | ₹108 to ₹114 per share |
| Offer Structure | Fresh Issue + Offer for Sale + Market Maker Reservation |
| Total Shares | 61,78,800 shares (aggregating up to ₹70.44 crore) |
| Market Maker Reserved Shares | 3,09,600 shares (₹3.53 crore) |
| Fresh Issue Shares (Ex Market Maker) | 53,29,200 shares (₹60.75 crore) |
| Offer for Sale Shares | 5,40,000 shares (₹6.16 crore) |
| Net Offered to Public | 58,69,200 shares (₹66.91 crore) |
| Issue Type | Bookbuilding IPO |
| Listing | BSE SME |
| Shareholding (Pre / Post) | 1,77,66,200 / 2,34,05,000 shares |
| Lead Manager | Oneview Corporate Advisors Pvt. Ltd. |
| Registrar | Kfin Technologies Ltd. |
| Market Maker | Mansi Share & Stock Broking Pvt. Ltd. |
| Investor Category | Shares Offered |
|---|---|
| QIB | Not more than 50% of the Net Offer |
| Retail (RII) | Not less than 35% of the Net Offer |
| NII | Not more than 15% of the Net Offer |
| IPO Open | Tue, Nov 11, 2025 |
|---|---|
| IPO Close | Thu, Nov 13, 2025 |
| Allotment (Tentative) | Fri, Nov 14, 2025 |
| Refunds Initiation | Mon, Nov 17, 2025 |
| Credit to Demat | Mon, Nov 17, 2025 |
| Listing (Tentative) | Tue, Nov 18, 2025 |
| UPI Mandate Cut‑off | 5 PM on Thu, Nov 13, 2025 |
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Individual Investors (Retail) (Min) | 2 | 2,400 | ₹2,73,600 |
| Individual Investors (Retail) (Max) | 2 | 2,400 | ₹2,73,600 |
| S-HNI (Min) | 3 | 3,600 | ₹4,10,400 |
| S-HNI (Max) | 7 | 8,400 | ₹9,57,600 |
| B-HNI (Min) | 8 | 9,600 | ₹10,94,400 |
Incorporated in 2002, Mahamaya Lifesciences Limited manufactures, registers, and exports crop protection products and bioproducts focused on crop and soil health management to boost farming productivity. The company specializes in pesticide formulations and supplies bulk products to Indian agrochemical companies and multinational corporations.
Mahamaya imports carefully researched molecules, registers them with the [Central Insecticides Board](pplx://action/translate), and markets technical and value-added formulations domestically and internationally. It has active markets in countries including Dominican Republic, Egypt, Ethiopia, Jordan, UAE, and Turkey.
Product portfolio includes bulk formulations, technical sales, branded products, and export formulations involving various pesticides and crop protection chemicals.
The company is known for its experienced management team, capability to introduce vital products for Indian agriculture, strong export market development, brand building, and supplier relationships focused on sustainability.
Financial Summary (₹ crore)
| Period Ended | 30 Jun 2025 | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|---|
| Assets | 218.87 | 188.35 | 112.07 | 77.88 |
| Total Income | 84.04 | 267.17 | 162.83 | 137.40 |
| Profit After Tax | 4.10 | 12.94 | 5.22 | 3.75 |
| EBITDA | 8.04 | 24.64 | 13.36 | 8.91 |
| Net Worth | 53.50 | 49.42 | 24.66 | 19.44 |
| Reserves & Surplus | 35.73 | 31.66 | 23.41 | 18.19 |
| Total Borrowing | 57.72 | 58.11 | 54.63 | 24.37 |
Source: IPO RHP and aligned financial disclosures as of 2025, figures in ₹ crore.
Interesting breakdown of the Mahamaya Lifesciences IPO. The focus on crop protection and soil health makes it a timely entrant in the agrochemical space, especially given the sector’s push toward sustainable farming. The relatively high minimum investment for retail investors might limit participation, but it’ll be worth watching how the listing performs given the company’s established export network.
Your point of view caught my eye and was very interesting. Thanks. I have a question for you. https://accounts.binance.info/lv/register-person?ref=SMUBFN5I